BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.

Also called NCT00910065

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 270 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT00910065
  • EudraCT 2007-005163-94
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, Germany, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT00910065. Randomized; no masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
Acronym
ACUTE
Condition
Acute Coronary Syndrome
Intervention (Drug)
D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV
Intervention (Drug)
D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV
Intervention (Drug)
Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct00910065
Content hash
161ee5e13f0276bbb3a0fd03479b28d8794872a0c4380f30fb24fd8a02880410